Brolucizumab injections may be associated with intraocular inflammation, with or without retinal vasculitis, and patient selection should take this into account, according to a speaker.
“Intraocular inflammation alone may often be managed with topical steroids, but optimal treatment for vasculitis remains unknown. This post-approval analysis is unable to assess rates or long-term outcomes, and further studies are indicated,” Paul Hahn, MD, said at Retina Subspecialty Day at the virtual American Academy of Ophthalmology meeting.
The American Society of Retina Specialists Research and
Uncategorized